Sugi Predict

Sugi Predict / Compounds / SCHEMBL2275445

SCHEMBL2275445

SCHEMBL2275445

CC(C)(C)OC(=O)N1CC(Oc2cccc(Br)c2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 3/20 0.51
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ RORC P51449 3/20 0.42
▸ GPR119 Q8TDV5 5/20 0.42
▸ CACNB4 O00305 1/20 0.41
▸ CACNA1A O00555 1/20 0.41
▸ CACNA1G O43497 1/20 0.41
▸ CACNG3 O60359 1/20 0.41
▸ CACNA1F O60840 1/20 0.41
▸ CACNA1H O95180 1/20 0.41
▸ CACNB3 P54284 1/20 0.41
▸ CACNA2D1 P54289 1/20 0.41
▸ CACNG7 P62955 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ CACNA1D Q01668 1/20 0.41
▸ CACNB1 Q02641 1/20 0.41
▸ CACNG1 Q06432 1/20 0.41
▸ CACNB2 Q08289 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29577158 0.90 USP30 (0.55) USP30GPR119MEN1KMT2A
SCHEMBL2112991 0.90 NR1H2 (0.46) USP30SLC6A2SLC6A4SLC6A3RORC
SCHEMBL2117772 0.90 NR1H2 (0.46) USP30SLC6A2SLC6A4SLC6A3RORC
SCHEMBL15637939 0.90 USP30 (0.55) USP30GPR119MEN1KMT2A
SCHEMBL30740748 0.88 GPR119 (0.55) USP30GPR119MEN1KMT2A
SCHEMBL1364255 0.88 GPR119 (0.55) USP30GPR119MEN1KMT2A
SCHEMBL12184833 0.86 USP30 (0.52) USP30RORCGPR119CACNB4CACNA1A
SCHEMBL29120062 0.86 GPR119 (0.52) USP30SLC6A2SLC6A4SLC6A3GPR119
SCHEMBL14874064 0.85 USP30 (0.54) USP30SLC6A2SLC6A4SLC6A3RORC
SCHEMBL31160904 0.85 USP30 (0.51) USP30RORCGPR119CACNB4CACNA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3852790-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X Forma Therapeutics, Inc. (US) 2021-07-28 — — EP disclosed
CN-113164571-A Inhibition of ubiquitin-specific peptidase 9X 福马治疗股份有限公司 2021-07-23 — — CN disclosed
EP-3186224-B1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS HOFFMANN LA ROCHE (CH) 2021-04-21 — — EP disclosed
WO-2020061261-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
CN-107001259-B Substituted azetidine derivatives as TAAR ligands 豪夫迈·罗氏有限公司 2019-12-06 — — CN disclosed
EP-3207042-B1 ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION IDORSIA PHARMACEUTICALS LTD (CH) 2018-10-03 — — EP disclosed
US-10023559-B2 Substituted azetidine derivatives HOFFMAN-LA ROCHE INC. (US) 2018-07-17 — — US disclosed
US-9850256-B2 Antibacterial basic biaromatic derivatives with aminoalkoxy substitution IDORSIA PHARMACEUTICALS LTD (CH) 2017-12-26 — — US disclosed
US-20170305927-A1 ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION IDORSIA PHARMACEUTICALS LTD (CH) 2017-10-26 — — US disclosed
EP-3207042-A1 ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION Idorsia Pharmaceuticals Ltd (CH) 2017-08-23 — — EP disclosed
EP-3186224-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. Hoffmann-La Roche AG (CH) 2017-07-05 — — EP disclosed
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-25 — — US disclosed
WO-2016059097-A1 ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION ACTELION PHARMACEUTICALS LTD (CH) 2016-04-21 — — WO disclosed
WO-2016030310-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2016-03-03 — — WO disclosed
US-8957059-B2 Modulators of serotonin receptors JANSSEN PHARMACEUTICA NV (BG) 2015-02-17 — — US disclosed
US-20140038934-A1 MODULATORS OF SEROTONIN RECEPTORS JANSSEN PHARMACEUTICA NV (US) 2014-02-06 — — US disclosed
US-8575364-B2 Modulators of serotonin receptor JANSSEN PHARMACEUTICA NV (BE) 2013-11-05 — — US disclosed
US-20110207709-A1 MODULATORS OF SEROTONIN RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038934-A1 MODULATORS OF SEROTONIN RECEPTORS HTR1A, HTR2A, HTR6 USP30 2632/4885SLC6A2 39/4885SLC6A4 19/4885
US-10023559-B2 Substituted azetidine derivatives HTR1B, MTNR1B, DRD2 USP30 1754/4885SLC6A2 157/4885SLC6A4 186/4885
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 USP30 12/4885SLC6A2 4458/4885SLC6A4 3862/4885
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HTR1B, MTNR1B, DRD2 USP30 1754/4885SLC6A2 157/4885SLC6A4 186/4885
US-20170305927-A1 ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION RPSA, RPL4, RPS4Y1 USP30 1237/4885SLC6A2 4245/4885SLC6A4 2887/4885
US-20110207709-A1 MODULATORS OF SEROTONIN RECEPTOR HTR1A, HTR6, HTR2A USP30 2765/4885SLC6A2 36/4885SLC6A4 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.